ZNF585B

Across TCGA pan-cancer cohorts, ZNF585B Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZNF585B data layer compared with 25 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ZNF585B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF585B expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

THYM, ESCA, and UCEC are the cancer types where ZNF585B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	21	view →
UCEC	DFS	Median	All	0.947	0.605	.005	20	view →
COAD	OS	Median	All	0.563	0.805	.006	9	view →
BLCA	OS	Median	III,IV	0.228	0.684	.023	6	view →
STAD	DFS	Median	All	0.211	0.709	.019	3	view →
LUSC	DFS	Median	All	0.775	0.364	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZNF585B–THYM (OS)

Open the THYM breakdown →